What's breaking now, across thousands of outlets.
Indian pharmaceutical company Gujarat Themis Biosyn has secured private credit financing to support its JPY21.5bn ($135m) acquisition of Japanese drugmaker MicroBiopharm Japan, according to a report by Bloomberg.
We haven't written up this one. Private Equity Wire has the full story — the link below goes straight to it.
Hao Dong, a former commodity portfolio manager at Singapore’s sovereign wealth fund GIC Pte., is starting a hedge fund that is seeking to raise as much as $300 million to invest in raw materials and…
Key PointsThe S&P 500 is on pace for its fourth consecutive year of double-digit gains amid strong financial results driven by heavy spending on AI.
Both companies generate billions in cash regardless of the economy.
Russia intensifies attacks on Ukraine’s data centers and communications infrastructure, targeting facilities in Kyiv.
Russia intensifies attacks on Ukraine’s data centers and communications infrastructure, targeting facilities in Kyiv.
Rabobank’s Global Daily notes that FX markets were surprised by Dollar strength in Q3, with EUR/USD and GBP/USD relatively subdued while USD/JPY saw “huge action” higher.
